Skip to main content

Table 2 Studies with biologic agents

From: Systemic therapy for recurrent or metastatic salivary gland malignancies

Author (year) Regimen No of patients Histology Progression required ORR CBR Median OS (months)
Haddad et al. [18] Trastuzumab 14 Ad (7), ACC (2), MEC (3), others (2) No 8 % 8 % NR
Hotte et al. [23] Imatinib 16 ACC (16) No 0 % 56 % 7
Pfeffer et al. [24] Imatinib 10 ACC (10) No 0 % 20 % NR
Guigay et al. [25] Imatinib 17 ACC (17) Yes 13 % 47 % NR
Agulnik et al. [19] Lapatinib 39 Ad (7), ACC (20), MEC (2), others (11) Yes 0 % 78 % NR (ACC), 13.8 (non-ACC)
Locati et al. [20] Cetuximab 30 ACC (23), MEC (2), others (5) No 0 % 80 % NR
Chau et al. [27] Sunitinib 14 ACC (14) Yes 0 % 85 % 18.7
Jaspers et al. [44] Bicalutamide 10 SDC (10) No 20 % 50 % 12
Locati et al. [29] Sorafenib 37 ACC (19), others (18) No 16 % 73 % NR
Thomson et al. [28] Sorafenib 23 ACC (23) No 11 % 79 % 19.6
Kim et al. [34] Everolimus 34 ACC (34) Yes 0 % 79 % 23.7
Goncalves et al. [37] Vorinostat 30 ACC (30) No 3 % 87 % NR
Hoover et al. [36] Nelfinavir 15 ACC (15) Yes 0 % 47 % NR
Ho A. et al. [30] Axitinib 33 ACC (33) Yes 9 % 85 % NR
Locati et al. [43] Bicalutamide + Triptorelin 17 SDC (17) No 65 % 88 % 44
Wong et al. [26] Dasatinib 54 ACC (40), others (14) Yes 2 % 50 % 14.5 (ACC), NR (non-ACC)
Jakob et al. [21] Gefitinib 36 Ad (9), ACC (18), MEC (2), others (6) No 0 % 59 % 25.9 (ACC); 16 (non-ACC)
Dillon et al. [32] Dovitinib 35 ACC (35) Yes 6 % 71 % 22.1
Ho A. et al. [35] MK-2206 16 ACC (16) Yes 0 % 93 % NR
Keam et al. [31] Dovitinib 32 ACC (32) Yes 3 % 94 % NR
  1. Ad adenocarcinoma, ACC adenoid cystic carcinoma, MEC mucoepidermoid carcinoma, NR not reported